Corrigendum to "Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma" [J Hepatol 46 (2007) 840-848] (DOI:10.1016/j.jhep.2006.11.021);Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma

Journal of Hepatology

Volumn 46, Issue 5, 2007, Pages 840-848

  Semela, David ^a   Piguet, Anne Christine ^a   Kolev, Mirjam ^a   Schmitter, Karin ^a   Hlushchuk, Ruslan ^b   Djonov, Valentin ^b   Stoupis, Christoforos ^c   Dufour, Jean François ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Angiogenesis; Intussusception; Liver; Mammalian target of rapamycin; Sirolimus

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASCITES; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; HEPATOMA CELL; HISTOLOGY; INTUSSUSCEPTION; LIVER CELL CARCINOMA; METASTASIS; MICROVASCULATURE; NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SURVIVAL; TUMOR GROWTH; VASCULAR RING;

EID: 34047118033     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.02.004     Document Type: Erratum

References (31)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
3. Llovet J.M. Treatment of hepatocellular carcinoma. Curr Treat Opt Gastroenterol 7 (2004) 431-441
4. Semela D., and Dufour J.F. Angiogenesis and hepatocellular carcinoma. J Hepatol 41 (2004) 864-880
5. Sun H.C., Tang Z.Y., Li X.M., Zhou Y.N., Sun B.R., and Ma Z.C. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 125 (1999) 419-426
6. Poon R.T., Ng I.O., Lau C., Zhu L.X., Yu W.C., Lo C.M., et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233 (2001) 227-235
7. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
8. Fingar D.C., and Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23 (2004) 3151-3171
9. Huang S., Bjornsti M., and Houghton P. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2 (2003) 222-232
10. Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., and Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24 (2004) 200-216
11. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., and Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10 (2004) 8421-8425
12. Rao R., Buckner J., and Sarkaria J. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 4 (2004) 621-635
13. Yang R., Rescorla F., Reilly C., Faught P., Sanghvi N., Lumeng L., et al. A reproducible rat liver cancer model for experimental therapy: introducing a technique of intrahepatic tumor implantation. J Surg Res 52 (1992) 193-198
14. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
15. Lowry O., Rosebrough N., Farr L., and Randall R. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
16. Grant D.S., Kinsella J.L., Fridman R., Auerbach R., Piasecki B.A., Yamada Y., et al. Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. J Cell Physiol 153 (1992) 614-625
17. Djonov V., Schmid M., Tschanz S.A., and Burri P.H. Intussusceptive angiogenesis: its role in embryonic vascular network formation. Circ Res 86 (2000) 286-292
18. Dufour J.F., Luthi M., Forestier M., and Magnino F. Expression of inositol 1,4,5-trisphosphate receptor isoforms in rat cirrhosis. Hepatology 30 (1999) 1018-1026
19. Djonov V.G., Kurz H., and Burri P.H. Optimality in the developing vascular system: branching remodeling by means of intussusception as an efficient adaptation mechanism. Dev Dyn 224 (2002) 391-402
20. Bruns C.J., Koehl G.E., Guba M., Yezhelyev M., Steinbauer M., Seeliger H., et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 10 (2004) 2109-2119
21. Guba M., Yezhelyev M., Eichhorn M.E., Schmid G., Ischenko I., Papyan A., et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (2005) 2004-2009-3540
22. Butzal M., Loges S., Schweizer M., Fischer U., Gehling U.M., Hossfeld D.K., et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 300 (2004) 65-71
23. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell 4 (2003) 343-348
24. Tsutsumi N., Yonemitsu Y., Shikada Y., Onimaru M., Tanii M., Okano S., et al. Essential role of PDGFalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo. Circ Res 94 (2004) 1186-1194
25. Patan S., Munn L.L., and Jain R.K. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 51 (1996) 260-272
26. Patan S., Tanda S., Roberge S., Jones R.C., Jain R.K., and Munn L.L. Vascular morphogenesis and remodeling in a human tumor xenograft: blood vessel formation and growth after ovariectomy and tumor implantation. Circ Res 89 (2001) 732-739
27. Djonov V., Andres A.C., and Ziemiecki A. Vascular remodelling during the normal and malignant life cycle of the mammary gland. Microsc Res Tech 52 (2001) 182-189
28. Guba M., Koehl G.E., Neppl E., Doenecke A., Steinbauer M., Schlitt H.J., et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18 (2005) 89-94
29. Abraham R.T. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 279 (2004) 299-319
30. Byrne A.T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J.I., et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9 (2003) 5721-5728
31. Mesiano S., Ferrara N., and Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153 (1998) 1249-1256